<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745144</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0031</org_study_id>
    <secondary_id>2018-001015-70</secondary_id>
    <nct_id>NCT03745144</nct_id>
    <nct_alias>NCT04086225</nct_alias>
  </id_info>
  <brief_title>Effects of Cladribine Tablets on the PK of Microgynon®</brief_title>
  <official_title>A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potential effects of cladribine on the&#xD;
      pharmacokinetics (PK) of monophasic oral contraceptive microgynon® by assessment of its&#xD;
      constituents, ethinyl estradiol (EE) and levonorgestrel (LNG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Plasma Concentration Time Curve From Zero to Tau at Steady State (AUCtau,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration From Time Zero to Tau at Steady State (Cmin,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at End of Dosing Interval at Steady State (Ctrough) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration at Steady State (Cave,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-to-Trough Fluctuation Over One Complete Dosing Interval at Steady State of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Cladribine</measure>
    <time_frame>Pre-dose up to 2.0 hour post-dose on Days 10, 11, 12, and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (tmax) of Cladribine</measure>
    <time_frame>Pre-dose up to 2.0 hour post-dose on Days 10, 11, 12, and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Electrocardiogram (ECG) and Laboratory Findings</measure>
    <time_frame>Up to Day 84</time_frame>
    <description>Number of participants with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Relapsing Multiple Sclerosis (RMS)</condition>
  <arm_group>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants will receive cladribine once-daily for 5 consecutive days in treatment period 1 and 2.</description>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.</description>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon®</intervention_name>
    <description>Participants will receive Microgynon® tablet once daily for 21 days in treatment period 1 and 2.</description>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are pre-menopausal women with or without child-bearing potential with a negative serum&#xD;
             pregnancy test, and women with child-bearing potential receiving adequate birth&#xD;
             control&#xD;
&#xD;
          -  Participants with diagnosis of clinically stable and definite relapsing multiple&#xD;
             sclerosis (RMS)&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function as defined in the protocol&#xD;
&#xD;
          -  Are able and willing to accept dietary restrictions and restrictions regarding the use&#xD;
             of concomitant medications (including over-the-counter products, herbal medicines and&#xD;
             dietary supplements) over the course of the study&#xD;
&#xD;
          -  Have a body weight and body mass index (BMI) within the range at screening&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to the active&#xD;
             substance or to any of the excipients of cladribine tablets or hypersensitivity to&#xD;
             drugs with a similar chemical structure to cladribine - History of clinically relevant&#xD;
             allergy or known hypersensitivity to 1 of the active substances levonorgestrel (LNG)&#xD;
             or ethinylestradiol (EE) or to any excipients of Microgynon® tablets&#xD;
&#xD;
          -  Positive results from serology examination for Hepatitis B surface antigen (HbsAg) not&#xD;
             due to vaccination, hepatitis B core antibody (HbcAb), Hepatitis C virus antibody&#xD;
             (anti- HCV) or Human Immunodeficiency antibody (anti-HIV)&#xD;
&#xD;
          -  Presence or risk of venous thromboembolism (VTE) arterial thromboembolism (ATE)&#xD;
&#xD;
          -  Diabetes mellitus (Type 1 or Type 2) with vascular manifestations&#xD;
&#xD;
          -  Signs or symptoms of neurological disease other than multiple sclerosis (MS) that&#xD;
             could explain the symptoms of the participant&#xD;
&#xD;
          -  Presence of gastrointestinal (GI) disease or history of gastrointestinal -tract&#xD;
             surgery&#xD;
&#xD;
          -  Exposure to another investigational drug within the last 2 months or within last 6&#xD;
             month if agent is known to be immunosuppressive&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Josef und St. Elisabeth Hospital gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroPoint</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Neurologie Dietenbronn GmbH - Diagnostisches und therapeutisches Kompetenzzentrum für Multiple Sklerose</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>M.A. - LEK A.M.Maciejowscy SC.</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioResearch Group Sp. z o. o</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>k.jarus@bioresearch.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Jarus-Dziedzic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IKARDIA Hospital Cardiology</name>
      <address>
        <city>Nałęczów</city>
        <zip>24-140</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp</name>
      <address>
        <city>Otwock</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0031</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cladribine</keyword>
  <keyword>Microgynon®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

